First semester 2013

  • Grant of the Marketing Authorization for Sitavig® in the US
  • Strong achievements in clinical trials with Livatag® (phase III) and Validive® (phase II)
  • Significant reinforcement of cash reserves thanks to the capital increase of July 2013
Biotest (TG:BIO)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Biotest Charts.
Biotest (TG:BIO)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Biotest Charts.